theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Gastroenterology

Immune-related adverse events   

Questions discussed in this category


In a patient with unresectable HCC who developed immune-related colitis with the first dose of tremelimumab/durvalumab, would you consider continuing durvalumab alone after resolution of the colitis with steroid treatment?
Would you consider a colonoscopy?
1 Answer available
24879


Papers discussed in this category


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Apr 11
Accelerating the Evolution of Immune-Related Enterocolitis Management.

Oncogene, 2023 Sep 21
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.

Related Topics in Gastroenterology

  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Gastrointestinal Cancers
  • Genitourinary Cancers
  • Melanoma/Skin Cancer
  • Pediatric Hematology/Oncology
  • Sarcoma
  • Thoracic Malignancies

Copyright © 2025 theMednet
All Rights Reserved.